Xofluza Approved for Postexposure Prevention of Flu
Influenza infection and symptoms occurred in 1 and 13 percent of those receiving Xofluza and placebo, respectively
CDC Recommends Three COVID-19 Tests for Americans Traveling Abroad
Tests recommended one to three days before the flight, three to five days after the flight, and one to three days before returning
First Drug Approved to Treat Rare Metabolic Disorder
Oxlumo granted approval to treat primary hyperoxaluria type 1
FDA Authorizes Use of Monoclonal Antibody Treatment for COVID-19
IV infusion of casirivimab and imdevimab authorized for treatment of mild-to-moderate COVID-19
Chimpanzee Adenovirus COVID-19 Vaccine Promising in Seniors
Immunogenicity similar across age groups; vaccine better tolerated in older versus younger adults
WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients
Evidence to date has not shown clinically important effects on mortality, need for mechanical ventilation
Third COVID-19 Vaccine Shows Effectiveness
The AstraZeneca vaccine becomes the third to show good effectiveness
AHA: Blacks, Hispanics Make Up 53 Percent of COVID-19 Deaths
Mortality, MACE rates among patients hospitalized with COVID-19 did not differ by race, ethnicity
Rates of VTE, Major Bleeding High in Primary CNS Lymphoma
Pulmonary embolism and major bleeding linked to increased mortality risk
FDA Issues EUA to Baricitinib Plus Remdesivir for COVID-19
Emergency use authorization applies to hospitalized patients requiring supplemental oxygen, mechanical ventilation, ECMO
